Ever thought of breaking the high-throughput sound barrier for drug discovery?

Aug 7, 2019 | Blogs, Pharma | 0 comments

Wouldn’t it be great if we really could “get time back” or even “buy time”? When developing pharmaceuticals, it takes years to bring a new therapy to the market due to the linear nature of the process. As the saying goes, “Time waits for no one.” But what if we could do more in the same period, effectively slowing time down? Then we would be in the favorable situation of having time on our hands.

In pharmaceutical development, many new compounds are screened for their effectiveness during the discovery process. The efficacy is determined by various tests to ensure that the compounds are effective and safe. Many analytical technologies, all with different capabilities, are employed to screen the vast numbers of compounds and deliver an analytical determination. Let’s take high-throughput screening (HTS) assays in pharmaceutical development as an example. Have you ever considered that these are potential bottlenecks to sample throughput today? Have you ever thought that the effort it takes to develop and validate an assay is overly time-consuming? Or been concerned that the results from HTS assays have high numbers of false positives/negatives that mean you spend even more time on data evaluation? Then mass spectrometry (MS) based systems could be the way to improve the selectivity of results, gain confidence in the data, and provide the ability to multiplex—allowing you to do more on a single system. But MS-based technology has its pitfalls, too. One potential bottleneck, particularly with MS-based detection, is that it often requires the use of liquid chromatographic (LC) separation to help with the removal of chemical and matrix-related interferences. This enhances compound ionization and thus selective detection, but adds time to the analysis. Up until today, some of the quickest analysis times with MS have been in the region of 1 sample every 15 seconds.

So, have you heard about Acoustic Ejection Mass Spectrometry technology (AEMS) recently introduced at ASMS 2019 by SCIEX? This technology has the potential to surpass the limits of sample analysis throughput and revolutionize HTS in both speed, accuracy, and precision. With the Echo MS system, the speed of analysis can be as fast as 3 samples per second—50 times faster than current MS-based assays. Your current and future high-throughput screening workflows can be transformed with this new frontier in contactless sampling. The Echo MS system combines the pioneering innovations of an Open Port Interface (OPI) and Acoustic Droplet Ejection (ADE) to form an Acoustic Ejection Mass Spectrometry system. Powerful but gentle in its approach, ADE technology is built into a liquid handler. It focuses ultrasonic acoustic energy at the meniscus of a fluid sample to eject small droplets of liquid (between 1 and 10 nL) from microtiter plates wells (96, 384 or 1536) into the OPI. That is where the very accurate droplets are transferred to a SCIEX mass spectrometer ion source for detection using mass analysis. This results in answers at speeds of up to 180 samples/min, or about 260,000 per day. The accuracy and precision of the assays benefit from the capability of mass spectrometry analysis to deliver <5% CV, along with high levels of uptime because of the use of the OPI in combination with the proprietary SCIEX OptiFlow® Turbo V source. Other key benefits include:

  • Eliminating tip cross-contamination through tipless transfer
  • Providing unsurpassed accuracy and reproducibility of results
  • Preserving sample integrity and viability during transfer
  • Increasing flexibility in transferring liquids at different positions and volumes
  • Reducing operating costs by eliminating disposable tips and reducing waste generation

Not convinced? Learn More >

Register your interest in AEMS and gain insight into the potential of this new technology over the coming months.

Pure and simple: Understanding LNP analytics for better mRNA-based drugs

A few years ago, it was discovered that messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) could result in mRNA adducts due to the breakdown products of N-oxide impurities. The ionizable lipids used in LNPs are especially susceptible to forming N-oxide impurities.

Is the next life-changing drug waiting to be analyzed in your laboratory?

In drug discovery laboratories, there is often a need to generate trusted analytical data on hundreds of thousands of drug candidates to allow confident decisions to be made. Sample prep, instrument run time, and data processing are all challenges that must be overcome.

Mass spec data across the cultivated meat value chain

We recently had the opportunity to chat with Alex Ward, PhD, Principal Consultant, Arta Bioanalytics to discover more about his work in developing transcriptomics and metabolomics data interpretation for the cultivated meat sector. As a specialist in multi-omics approaches, Alex is driving R&D, production and regulatory processes for the industry. Below are Alex’s responses to a few questions we asked, sharing his knowledge with the SCIEX community to drive the future of cultivated meat.

Posted by


Tags


0 Comments

Submit a Comment

Social Share Buttons and Icons powered by Ultimatelysocial